Beijing Tiantan Biological Products Corp Ltd (600161.SS) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE000000WF9

Price
12.72 CNY
Market cap
25.15 bn CNY
P/E (2025)
23.06
P/S (2025)
4.10
Dividend yield
1.18 %
Net margin
17.77 %
Return on equity (ROE)
7.08 %
Return on assets (ROA)
6.56 %

Beijing Tiantan Biological Products Corp Ltd financials

Fiscal year20242025
Revenue6.03 bn CNY6.14 bn CNY
Gross profit3.29 bn CNY2.58 bn CNY
Operating income2.56 bn CNY1.77 bn CNY
EBIT2.47 bn CNY1.77 bn CNY
Net income1.55 bn CNY1.09 bn CNY
Diluted EPS – continuing operations0.78 CNY0.55 CNY

Full history since 1995, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Beijing Tiantan Biological Products Corp Ltd

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally. Its products include human serum albumin; intravenous human immunoglobulin; rabies immunoglobulin; tetanus immunoglobulin; hepatitis B immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex concentrate; lyophilized intravenous hepatitis B immunoglobulin; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for injection; and other blood products. The company was founded in 1966 and is headquartered in Beijing, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 03.11.2026. Details in the risk notice.